Navigation Links
Pancreas in Medical Technology

WORLD'S First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center

... Stuart R. Geffner, M.D., Director of Kidney and pancreas Transplant Surgery, Saint Barnabas Health Care System Renal and pancreas Transplant Division, is the first in the world to ... found. They were referred to The Renal and pancreas Transplant Division at Saint Barnabas Medical ...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

... About Pancreatic Cancer The pancreas is a gland deep in the abdomen, behind the ... part of the digestive and endocrine systems. The pancreas makes juices that help with digestion (enzymes) ... Symptoms and Detection Since the pancreas is near the drainage tubes for bile and digestive ...

EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer

... cell growth in the tissue of the pancreas. The pancreas is an organ about six inches in length which ... screening for pancreatic cancer and, because the pancreas is hidden by other organs, it is difficult ... Americans will be diagnosed with cancer of the pancreas in 2007, resulting in approximately 33,000 ....

Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source

... in identifying the source of cancer stem cells in the lung, kidney, brain, pancreas and other tissues. "The idea that cancers might arise from ... to be a useful marker to trace cancer stem cells in the kidney, brain, pancreas and other tissues. The researchers are also exploring the use of stem cell ...

FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes

... the immune system destroys the insulin-producing beta cells of the pancreas that regulate blood glucose. Since the pancreas can no longer produce insulin, people with type 1 diabetes require daily ...

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

... is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence ...

Diabetes Gene Raises Odds of Lower Birth Weight

... in raising the risk of both lower birth weight and the development of type 2 diabetes in later life." Type 2 diabetes occurs either when the pancreas produces too little insulin or when the body cannot efficiently use the insulin that is produced. Formerly called adult-onset diabetes and still ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

... illness with long-term complications for our most vulnerable patients," said IMPACT Investigator, Dr. Robert Gaston, Medical Director for Kidney and pancreas Transplantation and Professor of Medicine, University of Alabama at Birmingham . "The IMPACT study gave us the opportunity to examine what has been ...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer

... by many solid cancers. The Company has conducted clinical trials with the naked and radiolabeled antibody in patients with colorectal, breast and pancreas cancers. In a lung metastatic model of colon carcinoma, therapy with labetuzumab-SN-38 conjugate increased median survival time (MST) 1.9- to ...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

... Receptor (GDIR) The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The GDIR signals through a similar intracellular pathway as the GLP-1 ...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

... Combination Treatment Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. Pramlintide is the active ingredient ...

Treatment Corrects Severe Insulin Imbalance in Animal Studies

... leader in diagnosing such lesions and performing the curative surgery on newborns. However, when abnormal cells are distributed throughout the pancreas in so-called diffuse HI, surgeons must remove nearly all the pancreas. This relieves HI in about a quarter of cases, but leaves the majority ...

Video: Sanford Health's Journey to Cure Type 1 Diabetes Receives Major Boost

... Krabbenhoft. "Through the Sanford Project, our research team will hope to either spur the body to copy existing functioning beta cells or to coax the pancreas to create new ones. When people with the disease have regenerated beta cells, they can begin making their own insulin again." Regeneration research ...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

... the same cells that make insulin. In patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes, those cells in the pancreas are either damaged or destroyed, resulting in reduced secretion of both insulin and amylin after meals. The use of SYMLIN contributes to glucose ...

Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...

Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity

... development of obesity treatments. About Pramlintide and Metreleptin Pramlintide is a synthetic analog of amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. Pramlintide is the active ingredient ...

CureDM's Diabetes Therapy Achieves Major Development Milestone

... much as 100-fold lower than the native form. HIP is a 14-amino acid human peptide derived from a specific human gene responsible for populating the pancreas with islets, which contain the cells that secrete insulin and other hormones necessary to prevent diabetes. "Meeting this milestone has a ...

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

... models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies. About Pancreatic Cancer Adenocarcinoma of the pancreas is a major unmet medical need and represents the fourth leading cause of cancer death in the US. Approximately 34,000 new cases of pancreatic cancer ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the U.S. Food and Drug Administration ("FDA") for use by people with type 2 diabetes who are unsuccessful at ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the U.S. Food and Drug Administration ("FDA") for use by people with type 2 diabetes who are unsuccessful at ...

Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells

... is the shortage of donor tissue supply. Patients often need a re-infusion of islet cells after the initial treatment, and this means another donor pancreas is needed to provide the fragile islet cells for transplant. New findings by researchers at the Diabetes Research Institute ( ...

Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas

... be more than 100,000 potential MRI images of the pancreas in the U.S. each year that could benefit from the ... to evaluate and treat diseases of the pancreas and gallbladder. There are risks associated with ... of normal and abnormal structures of the pancreas and to quantify pancreatic fluid production, ...

Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed

... one of the largest randomized phase III pancreas cancer clinical trials in North America and ... as First-Line Therapy of Patients with Advanced pancreas Cancer, questioned the benefit of using Cetuximab ... cancer. Next Generation of Clinical Trials in pancreas Cancer The emergence of molecularly targeted ...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

... within the body and radiation dose to the pancreas for intended therapy. Patients then received ... pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies ... therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and hCD74 as a therapy ...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

... from the disease in 2007. Because symptoms are non-specific, cancer of the pancreas is rarely diagnosed at an early stage leaving surgical removal of ... patients. The median survival of patients with operable cancer of the pancreas with currently available therapies is approximately 17 to 22 months. ...

Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets

... presented today revealed that the deletion or neutralization of LG842, a circulating protein expressed predominantly in adipose tissue, placenta, pancreas and liver, resulted in lower triglycerides and cholesterol in in vivo models. "Our in vivo studies, recently corroborated by human genetic data, ...

OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer

... The main risk factors for the disease include advanced age, cigarette smoking, a high-fat diet, diabetes mellitus, chronic inflammation of the pancreas (pancreatitis) - especially hereditary pancreatitis - and a family history of pancreatic cancer. The symptoms vary depending upon the location of the ...

Researchers Identify New Genetic Risk Factors for Type 2 Diabetes

... may influence other processes in the pancreas’s insulin-producing cells, known as beta cells. In addition, excessive activity of CDK5 in the pancreas may lead to the degeneration of beta cells. · CDKN2A and CDKN2B. The proteins produced by these two genes inhibit the activity of ...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

... as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and hCD74 as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes ...

Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases

... as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and hCD74 as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes ...

Eurand to Present Zentase Phase III Data

... . -- Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive enzymes normally produced by the pancreas that can result from a number of diseases, including cystic fibrosis, chronic pancreatitis, and pancreatic cancer -- EPI ...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

... as a potential therapeutic for patients with lymphoma and leukemia, (90)Y-epratuzumab for the therapy of patients with lymphoma, (90)Y- hPAM4 for pancreas cancer therapy and hCD74 as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes ...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

... glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA ...
Other Contents
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 HeartMath® ... authorities on stress, heart rate variability (HRV), heart ... licensing its extensive HRV databases and algorithms to ... opportunities will enable HeartMath’s partners to offer its ... extensive research, as well as its normative HRV ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
(Date:12/17/2014)... Hill, IL (PRWEB) December 17, 2014 ... 2015 Awards celebrate the best of the best in ... The award is only given to communities and agencies ... through the SeniorAdvisor.com site. Of the nearly 100,000 providers ... this award. Winners of the SeniorAdvisor.com Best of 2015 ...
(Date:12/17/2014)... Dec. 15, 2014 (HealthDay News) -- As gas prices ... deaths, a new study suggests. In times of ... of those riders are inexperienced, the researchers explained. ... California, which has the highest number of motorcycle registrations ... of motorcyclist deaths. The analysis revealed a strong ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Expectant parents should ... and Drug Administration recommends. Use of ultrasound imaging ... is not entirely risk-free, the agency warns. ... harm due to ultrasound imaging and heartbeat monitors, prudent ... is important," Shahram Vaezy, an FDA biomedical engineer, said ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
Other TagsOther Tags